Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran

摘要: Background: KRAS/NRAS/BRAF mutations are useful markers for predicting responses to anti- EGFR monoclonal antibodies in metastatic colorectal cancers. The aim of this study was investigate the clinicopathological characteristics and distribution by tumor localization KRAS cancer analysis NRAS BRAF patients Western Iran. Materials Methods: Between May 2008 November 2014, Thirty- three with or high risk CRC were included our study. DNA extracted FFPE QIAGEN Kit also KRAS/NRAS V600E analyzed using allele specific PCR primers pyrosequencing. overall survival plotted GraphPad Prism 5 software. Results: mean age at diagnosis 57.67±13.20 years (range, 28-80 years), 19 (57.6%) male. Of 33 patients, 9 (27.3%) rest had metastasis that more liver lung, respectively. 21 (63.6%) have wild-type 12 mutation. Also, samples checked NRAS. 20 months. Location 32 left-side colon. Conclusions: NRAS/BRAF testing should be used together genotype select who will likely benefit from anti-EGFR therapy location probably western Iran is on colon it needs other studies greater volume patients.